Hospital

The use of CGMs in pregnancy provides clinicians with essential data in real-time, rather than a snapshot given by traditional finger stick testing.

The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.

The study is expected to include 460 individuals that will be randomly treated with 12mg of ifinatamab deruxtecan or chemotherapy chosen by the health care provider.

A number of asthma-related emergency room visits are a result of viruses, but certain airborne pollens—notably Cupressaceae and tree pollens—are also contributors.

Dan Schrum discusses the integral role of pharmacy specialists in translating clinical trial results to clinical practice.

The findings may lead to the development of diagnostic and therapeutic targets to prevent worsening disease in patients.

neffy is an epinephrine nasal spray for the emergency treatment of allergic reactions in adults and pediatric patients.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

The primary end point of clinical remission at week 26 was met, with 36.7% of individuals treated with RHB-104 achieving clinical remission.

Intravenous Immunoglobulin as a therapy for patients with pyoderma gangrenosum could open new treatment avenues for the rare and challenging condition.

Dan Schrum highlights the crucial role of lymphodepletion in enhancing the effectiveness of CAR T cell therapy.

The injection adds an additional option to address emergency known or suspected opioid overdoses.

The indication is for the reduction of proteinuria in adult patients who have primary immunoglobulin A nephropathy and are at risk of disease progression.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

CD38 density may indicate the efficacy of monoclonal antibody treatment in patients with multiple myeloma.

Sunobinop binds to and activate nociception/orphanin-FQ peptide receptor, which is a known therapeutic target for substance use disorder.

A report from SkyQuest Technology highlights the growth in the oncology and insulin spaces, indicating they will contribute to the most growth.

The drug also receives orphan drug designation for the treatment of pancreatic neuroendocrine tumors and a Prescription Drug User Fee Act target action date of April 3, 2025.

Two different brands of intravenous immunoglobulin have been investigated, finding Brand P led to significantly longer durations of fever and hospitalization when compared to brand T.

The mRNA-1345 vaccine provides a one-off mechanism of protection because of its single-dose prefilled syringes

The findings highlight the potential for developing more efficacious combination treatments for patients with glioblastoma.

Zuranolone enhances health care providers’ ability to address the complex needs of patients with PPD, offering new hope for rapid and sustained relief from depressive symptoms.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

Afamitresgene autoleucel (afami-cel) is a novel cell therapy for the treatment of patients with synovial sarcoma.

Dolutegravir/lamivudine was non-inferior to bictegravir/emtricitabine/tenofovir alafenamide fumarate, meeting the study’s primary end point.

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.

Afami-cel was approved in conjunction with MAGE-A4 IHC 1F9 pharmDx, a diagnostic tool that can identify patients eligible to receive the treatment for synovial sarcoma.